Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

August 8, 2024

NASDAQ US Health Care Pharmaceuticals earnings 36 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Good afternoon, everyone, and thanks for being with us on today's call covering our business update and results for the second quarter of 2024. On the line with me are two of my colleagues: Lisa Delfini, who serves as Trevi's Chief Financial Officer, and Dr. David Clark, our Chief Medical Officer. I'll share some news about how our clinical trials are advancing, and then Lisa will walk through a short financial recap. After that, all three of us would be glad to take whatever questions you have. It's been an enjoyable yet demanding quarter here at Trevi, since we keep pushing forward on our clinical development programs — for chronic cough and idiopathic pulmonary fibrosis, or IPF, and also for refractory chronic cough, or RCC. Several data readouts should arrive before the year is over, and we aim to extend the impressive efficacy results from our Phase 2a study in IPF chronic cough. To keep up this rapid pace and stay focused on execution, we're continuing to strengthen our team, and we're delighted to share that in April we brought on Dr. Meg Garin, whose work was instrumental in advancing camlipixant's clinical development during her time at Bellus Health. Meg handles the day-to-day oversight of our RIVER trial and is already turning her attention toward planning the trial that comes next. She's proven to be an excellent addition. Now let me give a quick update on our clinical trials, starting with the Phase 2a RIVER trial in RCC, with data expected in this year's fourth quarter. RCC is a debilitating condition affecting roughly 2 million to 3 million adults in the U.S., and it's characterized by a cough that persists beyond eight weeks even after an underlying condition has been treated, or when no such condition is present. Given that no therapies are approved for RCC in the U.S. and that multiple drug candidates have failed, the unmet need remains substantial, and both patients and providers feel real urgency for new treatment options. We see Haduvio's main distinguishing feature as its mechanism of action, which acts synergistically in the brain centrally and in the lungs peripherally. In our view, this mechanism could potentially benefit a wider spectrum of RCC patients and might deliver a more pronounced effect across a broader range of baseline cough counts compared with mechanisms that act only peripherally. Our RCC study uses the typical Phase 2a crossover design employed in a number of cough trials conducted to date, and we plan to enroll about 60 patients. Randomization will use a 1:1 stratification — roughly 30 per arm — splitting those with moderate cough, meaning 10 to 19 coughs per hour, from those with high cough, meaning greater than or equal to 20 coughs per hour. Enrollment in this trial has been moving along well, and we've now reached approximately 80% of subjects enrolled. If we look at the rate we're seeing right now, our expectation is to share results from this trial during Q4 of the present year. That said, I should mention that at this moment there's a disparity among participants we've enrolled across our two stratification groups — specifically, the 10 to 19 and greater than 20 cough counts. Throughout the course of the study, the number of people enrolled in each of these arms has gone up and down. This kind of information matters for shaping what we do next in development, and it's possible we could reach our total target enrollment of 60 <<inaudible>> yet decide to keep the trial running a bit longer so the arms become balanced. We're eager to finish bringing patients into this study and to share the findings in this significant chronic cough indication. Now, turning to news about our leading program, which targets IPF chronic cough. IPF is a severe disease that occurs at the end of life. Roughly 85% of individuals with IPF experience chronic cough, which carries substantial physical, psychological, and social consequences. Coughing might additionally serve as a risk factor contributing to how the underlying illness advances. The ongoing damage to the lungs, tiny tears, and inflammation triggered by relentless coughing could result in poorer health outcomes for those patients. Since there are no approved therapies at present for chronic cough among IPF patients, both patients and physicians face a pressing demand for novel treatments. Our trial for IPF chronic cough, known as CORAL, is a Phase 2b parallel-arm dose-ranging study that will examine three active doses of Haduvio along with placebo. This six-week trial involves roughly 160 patients; we're running it across numerous countries and locations so that enrollment can be finished promptly. At this point, most of our sites are up and running, and enrollment is moving along well. We enjoy strong relationships with the trial's investigators and stay in frequent contact with them to keep our study a priority in their minds. The upcoming milestone for this trial involves performing a sample size re-estimation, or SSRE analysis, once 50% of patients have completed. An unblinded statistician from outside the company will handle this analysis, rerunning the power calculations with real data. The information we receive back will be quite limited, but we'll learn which of these three scenarios applies. First, proceed as originally planned with the current target patient count, confirming the initial powering assumptions. Second, the drug is performing within the pre-specified promising zone, but an increase in patient numbers will be needed to preserve the power. Or third, the drug isn't performing within the pre-specified range, and the company ought to think about halting. We'll disclose the findings of this analysis once we have that information, which we anticipate during Q4 of this year. Our expectation remains that topline data for the complete study will arrive in the first half of 2025, contingent on what the SSRE shows; additionally, we're running two key supportive trials this year — the human abuse potential, or HAP, study, and the respiratory physiology study. Let me bring you up to speed on each of those quickly. Enrollment for the HAP study stands at 95% right now, and one additional dosing cohort is needed before it's finished; full enrollment and dosing should be reached in Q3, and we anticipate reporting data from that trial in Q4. We've also kicked off a Phase 1 respiratory physiology study, which is designed to methodically assess respiratory function across differing degrees of disease severity and IPF, so we can pin down our Phase 3 patient population. Up to now, patients with sleep-disordered breathing have been left out of our clinical trials, and we're seeking a fuller picture of safety in the overall patient population. Approval for the protocol has come through in both the U.S. and the U.K., and screening of patients has begun. Roughly 25 patients are expected to be enrolled, staying inpatient for 10 days. The trial's primary endpoint is how escalating doses of Haduvio affect respiratory function, as measured through minute ventilation. Measures of additional respiratory functions are included as secondary endpoints. As you can see, these studies have moved along well, and the data they produce will matter a great deal in shaping the path forward for Haduvio in chronic cough conditions. My thanks go to our team, whose hard work has kept enrollment on plan. We're eager to finish these clinical trials and report the data starting in Q4 of this year. I'll hand things over now to Lisa for our financial results, and then we'll take any questions you might have.

Lisa Delfini

executive
#2

Thanks, Jennifer, and hello to everyone this afternoon. You can find the complete financial results for the 3 months that ended June 30, 2024 in the press release we issued before this call, as well as in our 10-Q, which we filed with the SEC today once the market had closed. For Q2 of 2024, our net loss came in at $12.4 million, versus a net loss of $7.1 million during the comparable quarter of 2023. R&D expenses reached $10 million in the second quarter of 2024, up from $5.8 million during the same quarter of 2023, a reflection of robust clinical activity across each of our 4 trials. G&A expenses came to $3.3 million in the second quarter of 2024, versus $2.5 million in the equivalent period of 2023, driven mainly by higher personnel and related expenses, market research costs, and information technology services. As of June 30, 2024, cash, cash equivalents, and marketable securities together came to $69.5 million, down from $83 million as of December 31, 2023. In the quarter, we issued roughly 1.5 million shares through our ATM, all bought by one buyer. That influx of cash bolsters our runway following data readouts on the clinical trials we are currently running; we still anticipate that, excluding proceeds from the share issuance, our cash burn will average $9 million to $12 million each quarter in 2024, and that our cash runway will extend into 2026. That wraps up our prepared remarks. I'll hand the call back to the Operator now for Q&A.

Analyst

analyst
#3

Hello. Jai Adam <<inaudible>> here, joining the call on behalf of Annabel. Nice work on the quarter's advances. Two things from me. First, about the chronic costs for RIVER. During trial design, were separate powering assumptions applied across the severity groups under investigation, or do they all share the same treatment effect power? Second, on the human abuse potential study. Could you verify that nalbuphine isn't a scheduled drug, whereas butorphanol is scheduled? Given that, would there be any basis for anticipating a dose response in likability with the ER formulation? And has the FDA given any signal of an intention to possibly reschedule nalbuphine ER? Thanks.

Jennifer Good

executive
#4

Yeah. Thanks, Adam. David will handle the powering assumptions per arm, and after that I'll address the remaining part.

David Clark

executive
#5

Yeah, no, thanks for asking that. So, as you're aware, the main endpoint for RIVER is the overall group of 60 patients. That's what the primary analysis covers. But what you're actually getting at is the subgroup analyses — and for those, we applied the very same effect-size assumptions.

Jennifer Good

executive
#6

Now, regarding the human abuse potential analysis, Adam — look, nalbuphine has existed for many years. The DEA has left it unscheduled, they review it on a routine basis, and they keep it that way. Beyond that, we possess a great deal of data on it. Every bit of the preclinical work has been completed. We hold our entire clinical database, and so forth; therefore, given our knowledge, we believe this drug ought to stay unscheduled. There's this one remaining item needed to meet today's requirements — the human abuse potential study. My guess is we'll conduct that study. We'll review the results. It will feed into the analysis. Roughly eight separate factors get examined, and that study is one of them. Still, I'd like to remind everybody that our drug's mechanism has two components — mu antagonists, and not one of those is scheduled, plus kappa agonists, and not one of those is scheduled either; so it strikes me as somewhat odd. Take butorphanol, simply for the sake of comparison: it's a weak mu-agonist and a kappa agonist, whereas we are a mu-antagonist and a kappa agonist. So I won't claim there's zero possibility of that occurring, yet we feel quite confident about our drug and haven't really observed problems there. Obviously, though, you must carry out the study and examine the results, after which we'll file all of it once we have them.

Analyst

analyst
#7

Okay, thanks a lot.

Jennifer Good

executive
#8

Yes, thanks, Adam.

Thomas Smith

analyst
#9

Hi, everyone. Afternoon. Appreciate you answering our questions, and nice work on the advances. Regarding the respiratory physiology trial, could you share what you anticipate for enrollment when it comes to how severe the patients' disease is that you're bringing into it? Also, please talk about which doses are going to be assessed there and how those line up against what you're examining in the IPF and RCC trials?

Jennifer Good

executive
#10

Absolutely. I'll hand that over to David.

David Clark

executive
#11

Much appreciated, and I appreciate you asking. So the amounts we're testing are identical to those found in both RIVER and CORAL. In that inpatient trial, we're looking at as much as 108 milligrams BID. And apologies, the initial portion of what you asked was...

Jennifer Good

executive
#12

How severe the disease is, the healthcare...

David Clark

executive
#13

Essentially, the study begins with the same patient population we're looking at in CORAL. That means the IPF diagnosis, and basically the same group of patients. Then, after we've gathered data from that first cohort, the plan is to broaden the population, which is what we've said before, so that sleep disordered breathing subtypes are covered. So all forms of sleep disordered breathing would get incorporated into the study at that point. That way we can tackle the main question — because for Phase 3, our aim is to enroll a wide spectrum of IPF patients, which lets us answer that question.

Thomas Smith

analyst
#14

Understood, that helps. Then, if I may ask something further regarding RIVER, could you go into more detail about how enrollment is split between moderate and severe patients that you're observing? Is the number of moderate patients greater, or is it severe? Also, is there any additional baseline characteristic you can see that might be different from what you first anticipated, or from other recent Phase 2 RCC trials?

Jennifer Good

executive
#15

Right; Tom, we don't make comments about every particular detail inside the study while it's ongoing, since the situation shifts. What I'd say is there is a certain amount of imbalance, though it has moved in each direction. At one moment, one arm is somewhat ahead of the other. So once we reach the end, we'll present all of that broken out by subgroup. Regarding baseline characteristics, I'm able to tell you that when Meg joined, she reviewed essentially every subject who had been enrolled along with all of their medical records. And David, feel free to add something too, and she thought it appeared fine, with proper diagnoses, and nothing out of the ordinary given what she observed.

David Clark

executive
#16

That's exactly correct. I mean, that matches what we anticipated. There's an upside to these Phase 2a trials being on the smaller side. You're able to run your study at truly top-tier, highly specialized sites, so that lines up with what we anticipated, and it's also what we've observed.

Jennifer Good

executive
#17

Yeah. Thank you, Tom, for the question.

Thomas Smith

analyst
#18

That's useful. Yeah. I appreciate you answering our questions, and I'm eager for the fourth-quarter updates.

Jennifer Good

executive
#19

Wonderful.

Leland Gershell

analyst
#20

Hello there. Afternoon to you. Appreciate you fielding what we have to ask. My question is this: when you consider how the development programs are shaping up, with the RCC topline readout approaching, and with Haduvio still being developed for IPF chronic cough, does what happens in the RCC trial change anything about the IPF strategy? Put differently, might you decide to put Haduvio first in RCC? Would that shift how much weight the IPF opportunity carries? I'm simply curious how you weigh those two against each other if RCC delivers a robust data set. Thanks.

Jennifer Good

executive
#21

Yes. That's a fair question, Leland. It's something our team and our board discuss frequently. Within Trevi there is a strong commitment to IPF being our lead indication. The unmet need is severe, those patients don't have many options, and cough represents a major issue. Also, as I mentioned during my comments, we think cough may be adding to the disease underneath, so we could examine certain endpoints in an exploratory fashion. RCC stands out since unmet need exists there too, and the way it ultimately fits together with IPF is something we'll need to grapple with. My sense is that Trevi would aim to capture the greatest — provided the P2X3 camlipixant wins approval, we'd likely position ourselves as third-line therapy following it, for patients who fail, since we'd want to preserve the pricing we hold in IPF. As we see it now, that's likely the best route to maximizing the drug's value. Of course, in another company's hands, one with a larger sales force, that might not hold true; so my thinking is this, if the data backs it up: Trevi will take the lead with its IPF program while studying RCC with an eye toward capturing the most severe coughers who find relief nowhere else. Incidentally, that could include those in this moderate cough count, should they be unable to get treatment. But that's — we ran some modeling over the summer, and I believe that's how we can best optimize it.

Leland Gershell

analyst
#22

Great. I really appreciate the additional detail.

Jennifer Good

executive
#23

Yes. Thanks, Leland.

Mayank Mamtani

analyst
#24

Hello everyone, and thanks for fielding our questions. Congratulations on the advancement. Regarding the Phase 2a RIVER protocol, would you remind us what sets it apart from the Phase 2a CANAL you ran earlier with such strong results? Then I have one quick follow-up.

David Clark

executive
#25

I appreciate that question. The design, as you're aware, is basically identical. What we changed was solely informed by the early efficacy signal observed in the CANAL design, in which dosing reached 162 milligrams BID; we set the maximum dose at 108 BID. So the dose came down relative to CANAL, and we extended the washout period to as much as three weeks. One other small distinction exists. CANAL took place while COVID was circulating heavily, and we were only able to capture the objective cough endpoint at baseline during week three. In this case, we returned to the approach where weekly objective cough data could be collected, which had always been the goal in CANAL, though COVID interfered.

Mayank Mamtani

analyst
#26

That's quite useful. Thanks. Now regarding the PROs — everyone recognizes this is a significant regulatory matter as well — would you mind reminding us what you expect from CORAL, clearly? And will RIVER additionally provide us with further details about a few of those PROs? Then I have one additional question following that.

Jennifer Good

executive
#27

Yes. David?

David Clark

executive
#28

Right, so we broadened the set of PROs, and I'll begin with CORAL before getting to CANAL. In CORAL, we essentially are able to characterize patients using a cough frequency score — that's what we're employing, and it was the identical endpoint used during Phase 2a in CANAL. Beyond that, we've widened things considerably with Living with IPF. There are plenty of PROs here, letting you develop a solid sense of the general clinical picture and the gains achieved, among them functional improvements; so the PRO coverage is quite broad. Then there's the cough questionnaire, which you'd anticipate. Living with IPF is an excellent tool; after that come standard anchor measures — patient global impression of severity, plus change in cough and IPF. Those are the kinds of measures involved. They rank among the key PROs we introduced there; and honestly, we followed a comparable path even in the small RIVER study. In that case, the key secondary PRO endpoints would again be cough frequency, the cough questionnaire, and cough severity. We're relying on the VAS measurement, since most RCC programs use it, making it a solid comparison against other programs; at some point we might move to the cough severity NRS measurement, because from a regulatory standpoint that would likely serve as a superior endpoint for approvals, though that's a fairly minor point. And then, once more, a solid anchor via patient global impression of severity and change in cough within the RIVER study too.

Mayank Mamtani

analyst
#29

That's quite useful, thanks. Then one last thing—regarding what you mentioned before, Jennifer, about concentrating on the severe cough group, or perhaps those who don't respond to P2X3. Did that come about more recently, or will it simply depend on the data you get from RCC? I bring this up since the dose-ranging effort you're finishing could yield a separate dose for those two distinct indications. So…

Jennifer Good

executive
#30

Right.

Mayank Mamtani

analyst
#31

… I was just curious how tied you are to the idea of…

Jennifer Good

executive
#32

Yeah.

Mayank Mamtani

analyst
#33

… tying your strategy to chronic cough indications. J It's a fair question, Mayank. As I mentioned, we discuss this quite a bit. I'd say it emerged from some effort this summer, and you're correct. Everything will hinge on the data. Clearly, these represent two major indications, with substantial unmet need in each; so there's plenty of opportunity there. What we've been grappling with, being a small company, is this. IPF is very — we can carry that all the way to approval, and if commercialization were needed, it requires a highly specialized sales force. So that model feels quite manageable to us. RCC begins to open that up much more widely. So our colleague has spent much of this summer trying to determine how you might preserve the premium pricing we believe is achievable in IPF when moving into an RCC population. But none of those choices are settled yet. I'd simply say it likely stems from some research this summer and consideration of how to optimize things without cannibalizing IPF. That's where our thinking stands now. On the flip side, though, the RCC market is large enough, and that's my point. In another company's hands, there's already a sales force in place. You could imagine them launching far more broadly since they lack the costs tied to establishing one; so you're right; it will depend on data. It's truly not a decision we must make for some time. I mean, we'll keep going; we'll conduct the next study. But eventually, someone will have to tackle that question. Yeah. That makes perfect sense, and it's good to be proactive about it. Thanks once more for taking our questions, and we look forward to your upcoming updates.

Jennifer Good

executive
#34

Yeah. Thank you, Mayank.

Brandon Folkes

analyst
#35

Hi, thanks for fielding my questions, and congrats on everything you've accomplished. First off, regarding the HAP data readout, when it comes to calling it a positive result, is the bar really just that we don't observe dose-dependent likability — that alone counts as positive for you and bolsters your talks with the agency? So even if likability runs high in one arm — and I'm sure some likability will show up — as long as it isn't dose-dependent, should we read that as a win and as strengthening your dialogue with the agency?

Jennifer Good

executive
#36

Brandon, good question. As with any data, it comes down to the overall picture of what emerges. There's a published paper Cara authored involving their kappa agonist, in which they demonstrated separation from placebo, yet that compound was less likable than pentazocine, their comparator. Since only a single dose was tested, the question of dose-response never arose. That drug ended up unscheduled. So on a baseline level, we'll probably separate from placebo, but with any luck we'll be less likable, or comparable, relative to our comparator. That, I think, places us in a strong position. That said, you're correct that the FDA's real worry is this: if a little bit of signal and likability appears, you don't want to observe dose dependence, since nobody wants a situation where someone likes it somewhat, then takes roughly 3x the dose, and ends up liking it 3 times as much. So it's a combination of all those factors. It's definitely something we'll examine; however, our expectation is that this drug shouldn't be particularly likable. After all, you've seen our adverse events profile, and that just isn't what we observe. Once we have the full dataset, we'll present it to the street, and we'll also bring in an expert to help interpret what we've found, along with our own conclusions about it.

Brandon Folkes

analyst
#37

Excellent, that's really useful. Perhaps we can now turn to the respiratory trial, and could you describe what you see as the main obstacle at this point for getting sleep disorder patients enrolled later on? Or is this more about producing the evidence first and then speaking with the regulator about whether that's sufficient to cover those sleep disorder patients, or do you believe there's a specific bar the agency has set that must be met?

David Clark

executive
#38

When it comes to the respiratory physiology study, I'd say there are well-recognized endpoints and markers for determining what counts as a clinically meaningful shift in minute ventilation, and that, for instance, serves as the primary endpoint we're able to use. So in fact, we expect that once the data comes in, we'll be able to interpret the study's signal on our own reasonably well, since in actual clinical practice there is quite clear guidance regarding what constitutes a clinically meaningful change across all the endpoints under examination. Therefore, we're confident that we ourselves will be able to interpret the study's findings. It's not — our view is certainly not that we must — that it's obligatory for us to return to the FDA and engage in some kind of dialogue. During an end of Phase 2 meeting, we'll have this dataset available, but we expect it to be more straightforward than, no, here's an in-depth conversation regarding the significance of each of these results.

Brandon Folkes

analyst
#39

Thanks. That’s quite useful; and then perhaps finally, just building on some of those earlier remarks, specifically regarding the RIVER imbalance across the two arms. You mentioned how this has shifted back and forth over the course of the study. Is that simply a typical element of the fluctuation and of that cycle, or has one patient group turned somewhat more competitive to enroll as we move forward? I realize you aren’t providing detail on which patient group, but is there essentially a basic competition for one of these patient groups, or is it merely ordinary fluctuation? Thank you.

David Clark

executive
#40

So we constantly anticipated — thank you for the question. We constantly anticipated — one group is always going to recruit somewhat quicker than the others, but we anticipated — we didn’t — weren’t forecasting which one, honestly. The distinction here that Jennifer was referring to is the distinction was somewhat bigger than we anticipated, and that’s why, as we’ve consistently clarified, we believe roughly 30 subjects per group in these two subgroups, the 10 to 19 and the greater than 20 patients, will enable us to detect a clinically meaningful effect size. We’ve got more than 80% power in both of these subgroups with about roughly 30 subjects to detect a mid-30% effect size on top of placebo; and for that reason, we believe it’s important to remain with that stated aim, and that’s what Jennifer was referring to. So the distinction was — the imbalance was somewhat bigger than we were anticipating when we began the study, but we always knew there’d be one group that would recruit faster.

Jennifer Good

executive
#41

Also, it comes down to maybe 1 or 2 months of hiring, so we'll simply watch how it shapes up; this problem might disappear. I'm merely reminding everyone about the protocol and that it might surface when the study concludes.

Brandon Folkes

analyst
#42

I really appreciate it. That's always quite useful.

Jennifer Good

executive
#43

Yes.

Brandon Folkes

analyst
#44

And well done on the advancements.

Jennifer Good

executive
#45

Thanks, Brandon. Glad to have you keeping track of us.

John Gionco

analyst
#46

Hello, John here, filling in for Serge right now. We appreciate you answering our questions. To start, regarding the intellectual property around nalbuphine, could you walk us through what the existing patent protection looks like, whether there are any further filings still pending right now, and if the…

Jennifer Good

executive
#47

Yes.

John Gionco

analyst
#48

Yeah.

Jennifer Good

executive
#49

That's a great question, John, and I appreciate it. So what we've done is obtain method-of-treatment patents; there's also a family of formulation patents covering the product out to about 2030, but the method-of-treatment patents we've secured — which really form the heart of the protection — run through 2039 for IPF. We hold worldwide rights and patents that we've pursued covering that. On top of that, there are further applications in prosecution relating to additional clinical work we've completed around the label, such as dosing for elderly patients or those who are hepatically impaired or renally impaired, and we'll likely secure some IP possibly from our human abuse potential study. So those types of patents currently in prosecution would in fact push this out to 2041 for one group and 2043 for another group. But I view the method-of-treatment protection running through 2039 as essentially the core of the patent coverage. When it comes to refractory chronic cough, that generally sits under the same umbrella. We're awaiting our data from this RIVER study, and after that we'll prosecute the actual claims based on the data we observed, file them as track one claims, and those ought to issue as well; we drafted the overall invention with the expectation that we'd be examining IPF, other interstitial lung diseases, and refractory chronic cough. And we draw from that application once we have actual data in hand so the claims can be issued.

John Gionco

analyst
#50

Great, that sounds good. I just have one quick follow-up question. Could you talk about the patient population right now for RCC — specifically, how many people get diagnosed, and how many are actively looking for treatment? I'm just hoping for a bit more detail there. Thanks.

Jennifer Good

executive
#51

Yeah, that's a good question. Some of that information is in our corporate deck, and my commercial colleague isn't on the line with us. We think there are roughly 2 million to 3 million treatable patients in the U.S.; it's a large indication. I believe around 7 million patients are diagnosed in the U.S. But once you narrow that down to the people who are seeking treatment and not receiving proper care, it comes down to somewhere around 2 million to 3 million patients. If you'd like, John, we can follow up on that, and I can get Farrell on the call, and we can provide you with a better walk-down.

John Gionco

analyst
#52

Fantastic. That's really encouraging, and congratulations once more on how far things have come.

Jennifer Good

executive
#53

I appreciate you asking.

Debanjana Chatterjee

analyst
#54

Hello. I appreciate you letting me ask. Can you hear me clearly?

Jennifer Good

executive
#55

Yes, I can.

Debanjana Chatterjee

analyst
#56

Yeah. Okay, so I was wondering, what sort of lag are you expecting for the RCC data readout as a result of this imbalance? And I've got another question after that.

Jennifer Good

executive
#57

I don't — well, as I sit here right now, no delay is what I anticipate. We have reaffirmed — confirmed our guidance for Q4 of this year; enrollment stands at 80%. So the only reason I raise this matter is that if we reach the end and decide to keep the trial running in order to, well, we won't keep it running beyond 1 or 2 months at the absolute maximum so that those arms reach balance. And it's possible that won't even — even that won't be necessary. So as things stand, no delay is expected on my part. I'm merely noting that executing on that was something we truly hoped to include in our protocol to obtain the information.

Debanjana Chatterjee

analyst
#58

Yes. That’s quite useful. Thank you. Perhaps one more question. As you said, if you choose to head up and carry out the RCC program by yourself, you might be thinking about that in the third line. What do you figure the size of that opportunity is? What’s the patient count — how many are there?

Jennifer Good

executive
#59

Yeah. We haven’t disclosed every piece of that; there’s a great deal of work happening this summer; it’s a large patient opportunity. With many of the P2X3s — I’m aware you’ve tracked that area, Debanjana — they fail to work in roughly 30% to 40% of patients. For some patients where they do work, the cough is extremely severe, and despite that, the cough reduction isn’t total. So there’s a sizable opportunity for this group, which truly has few choices. So our market research is being wrapped up. Eventually, we’ll share our perspective on it and how that flows down. But we see it as a very substantial market opportunity, especially given that very few — not many competitors remain in this space.

Debanjana Chatterjee

analyst
#60

Yeah. Thanks a lot.

Jennifer Good

executive
#61

Yeah. Thank you.

Jennifer Good

executive
#62

We appreciate everyone being here. Over the coming months, we anticipate a consistent stream of updates concerning the data from our clinical trials, and we're eager to pass those along to you. During the next couple of months, we'll be taking part in a number of investor conferences, which are detailed in our press release, and with any luck, some of you will be there with us. Thanks for being on this call, and once we finish, we'll be around to take whatever questions you might have.

Operator

operator
#63

That brings our meeting to a close. We appreciate everyone joining us for this presentation today. You're welcome to leave the call now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.